ZYME Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Buy now. ZYME is sitting just above first support (~22.26) with weakening downside momentum (MACD negative but improving), while Wall Street sentiment has turned strongly bullish with multiple recent Buy/Outperform/Overweight ratings and price targets clustered in the low-to-mid $30s up to $40. With no negative news flow in the past week and a royalty-focused strategy narrative gaining traction, the risk/reward favors initiating immediately rather than waiting for a “perfect” entry.
Price/levels: Closed at 22.55, hovering just above S1=22.263 and below Pivot=23.145 (near-term overhead). A push back above ~23.15 would improve upside follow-through toward R1=24.03. Momentum: MACD histogram -0.165 remains below zero (bearish), but is negatively contracting, suggesting selling pressure is fading. RSI: RSI(6)=34.2 is near the lower end of neutral and close to oversold conditions, consistent with a near-support rebound setup. Trend: Moving averages are converging, typically signaling consolidation and potential inflection. Pattern-based forward bias: Similar-pattern stats imply mild downside next day (-0.08%) but improving odds over 1 week (+2.78%) and 1 month (+21.75%), aligning with a swing-long bias from support.
Strong, recent analyst upgrades/initiations tied to royalty-aggregation strategy and zanidatamab (Ziihera) milestones/royalties.
Prior disclosed Phase 3 HERIZON-GEA-01 success narrative continues to support expectation of additional approvals (notably GEA opportunity into 2H26 per analyst commentary).
Technical setup: trading near support with momentum deterioration slowing, increasing odds of a bounce.
No negative news in the last week, allowing bullish thesis to dominate positioning.
Options flow shows near-term defensive posture (put volume outweighing calls), implying traders are still hedging downside.
Profitability remains negative (net loss and negative EPS), so the stock is still dependent on execution/milestones/royalty ramp.
Price is below pivot resistance (~23.15); failure to reclaim it can keep the stock range-bound in the short term.
Latest quarter: 2025/Q3. Revenue grew to $27.61M (+72.59% YoY), showing strong top-line momentum. However, net income was -$19.60M (more negative YoY by ~34%), and EPS was -$0.26 (more negative YoY by ~33%), indicating the business is still loss-making despite revenue growth. Gross margin was reported at 100%, consistent with a partner/royalty-style revenue mix rather than traditional product COGS.
Recent trend: Clear, accelerating bullish shift from mid-Nov to mid-Dec 2025. Multiple firms raised targets sharply (e.g., Citi to $35, Leerink to $37/$40, Stifel to $40, B. Riley to $40, H.C. Wainwright to $32), plus new coverage with Buy/Outperform and $32-$40 targets; Wells Fargo upgraded to Overweight with a $33 target. Wall Street pros: (a) royalty/milestone monetization and “de-risked cash flow” framing, (b) confidence in zanidatamab/GEA opportunity and additional catalysts, (c) valuation argued as attractive vs modeled royalties. Wall Street cons: (a) some lingering skepticism on the durability/visibility of the broader royalty-aggregation strategy beyond the lead asset, (b) continued net losses. Influential/political trading: No recent congress trading data available; hedge fund and insider trend indicators are neutral.
Intellectia Proprietary Trading Signals
